This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

TachoSil Paediatric Liver Trial (TC-019-IN)

This study has been completed.
Information provided by:
Nycomed Identifier:
First received: August 16, 2006
Last updated: May 4, 2012
Last verified: July 2008
The overall objective is to assess the haemostatic efficacy and safety of TachoSil for control of local bleeding in paediatric patients undergoing surgical resection of the liver with our without segmental liver transplantation.

Condition Intervention Phase
Liver Diseases Drug: Fibrinogen human (TachoSil) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective, Multi-centre Phase III-b Study of TachoSil in Paediatric Patients Scheduled for Resection of the Liver With or Without Segmental Liver Transplantation.

Resource links provided by NLM:

Further study details as provided by Nycomed:

Primary Outcome Measures:
  • The primary objective is to collect data on efficacy, i.e. intra-operative haemostasis, and safety of TachoSil ® as treatment to control local bleeding in children undergoing surgical resection of the liver with or without segmental transplantation. [ Time Frame: 7½ months ]

Enrollment: 16
Study Start Date: October 2005
Study Completion Date: May 2008
Intervention Details:
    Drug: Fibrinogen human (TachoSil)
    Resection of the liver with or without segmental liver transplantation

Ages Eligible for Study:   up to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Has the parent(s)/legal guardian given informed consent according to local requirements before any trial related activities?
  2. Is the child above 4 weeks and below 6 years of age?
  3. Has at least segmental resection (anatomical/non-anatomical) of the liver and primary haemostatic treatment been performed? or Has resection of the liver and placement of a segmental liver graft and primary haemostatic treatment been performed?
  4. Is only minor, i.e. oozing, or moderate haemorrhage persisting after primary surgical haemostatic procedures of the major vessels (no pulsating arterial haemorrhage and/or major venous bleeding)?

All inclusion criteria must be answered "yes" for a child to participate in the study.

Exclusion criteria:

  1. Was the child retransplanted or had liver transplantation in combination with other organs?
  2. Was there anamnestic or laboratory evidence of congenital coagulation disorders including Haemophilia A or B and von Willebrand disease?
  3. Has the child a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin?
  4. Has the child fulminant hepatic failure, portal vein thrombosis or anamnestic or clinical evidence of cirrhotic condition of the liver, including cirrhosis due to genetic deficiency of a1 - Antitrypsin?
  5. Did the child undergo an emergency operation?
  6. Does the child participate in another clinical trial during the intra-operative phase?
  7. Has any serious surgical complication occurred?
  8. Has any fibrin glue haemostatic (including TachoSil ® ) been used on the target wound before the planned application of TachoSil ® ? To participate in the study all exclusion criteria must be answered "No" for a child having segmental resection. For a child having total hepatectomy and placement of a segmental liver transplant criteria 4 and 5 can be answered "Yes".
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00365248

Roskilde, Denmark, 4000
Sponsors and Collaborators
Study Chair: Clinical Trial Operations Headquaters
  More Information

Responsible Party: Nycomed Identifier: NCT00365248     History of Changes
Other Study ID Numbers: TC-019-IN
Study First Received: August 16, 2006
Last Updated: May 4, 2012

Keywords provided by Nycomed:
Surgical resection of the liver with or without segmental transplantation

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases processed this record on August 16, 2017